01 Increasing Outsourcing of Specialized Pharmaceutical Manufacturing Healthcare companies are increasingly using contract manufacturers for specialized production activities that require dedicated facilities, technical expertise, and established quality systems. Outsourcing allows pharmaceutical and biotechnology companies to access manufacturing capabilities without developing equivalent internal infrastructure, particularly for complex formulations, sterile products, and specialized production processes. In August 2025, the U.S. Food and Drug Administration launched the FDA PreCheck initiative to facilitate the development of pharmaceutical manufacturing capacity and strengthen manufacturing supply chains, highlighting the increasing importance of specialized production infrastructure.
02 Growing Adoption of Flexible Manufacturing for Biopharmaceutical Products Contract manufacturers are increasingly developing flexible production capabilities that can accommodate multiple biopharmaceutical modalities and changing client requirements. Flexible facilities can support smaller production runs, technology transfers, process development, and manufacturing scale-up as products progress through clinical development and commercialization. This is increasing the value of outsourcing partners beyond basic production services. In September 2025, the U.S. Food and Drug Administration held a public meeting on domestic manufacturing of drugs and biological products, highlighting the need for manufacturing capabilities that can support emerging pharmaceutical and biotechnology products.
01 Increasing Complexity of Healthcare Product Manufacturing Developing all required capabilities internally can be costly and time-consuming, encouraging healthcare companies to use external manufacturers with established technical infrastructure. Manufacturing complexity therefore supports continued demand for contract outsourcing.
01 Loss of Direct Manufacturing Control Can Limit Outsourcing Decisions Outsourcing production can reduce a healthcare company's direct control over manufacturing schedules, process changes, quality systems, and production priorities. Dependence on an external supplier can also create coordination requirements between the contract manufacturer and the sponsoring company. These considerations can discourage outsourcing when companies view internal production control as strategically important.
01 Expansion of Domestic Manufacturing Creates New Outsourcing Capacity Efforts to strengthen domestic healthcare-product supply chains are creating opportunities for contract manufacturers to establish or expand production facilities closer to pharmaceutical and medical-device customers. Domestic outsourcing can reduce dependence on distant manufacturing networks while providing healthcare companies with access to qualified external capacity. Investment in local production infrastructure can therefore create additional outsourcing opportunities.
01 Maintaining Consistent Quality Across Outsourced Production Networks Contract manufacturing can involve multiple facilities, suppliers, laboratories, sterilization providers, and other external partners. Maintaining consistent quality across these interconnected operations requires effective auditing, documentation, change control, traceability, and communication. Failure to coordinate these activities can create regulatory and product-quality risks for both the contract manufacturer and healthcare company.
June 2026 Samsung Biologics expanded its contract development and manufacturing organization (CDMO) capabilities by opening additional biologics manufacturing capacity, strengthening support for global pharmaceutical and biotechnology companies.
April 2026 Lonza Group announced the expansion of its sterile fill-finish manufacturing network through new facility investments, enhancing outsourced manufacturing services for biologics, vaccines, and advanced therapeutics.
January 2026 Catalent, Inc. expanded its injectable manufacturing capabilities by adding new high-speed production lines and advanced aseptic filling technologies to support growing demand for outsourced pharmaceutical manufacturing.
October 2025 Thermo Fisher Scientific expanded its pharmaceutical contract manufacturing services by investing in additional sterile manufacturing capacity and advanced drug product development capabilities for global healthcare customers.